In accordance
with 5 CFR 1320, the information collection is not approved at this
time. Prior to publication of the final rule, the agency should
provide to OMB a summary of all comments received on the proposed
information collection and identify any changes made in response to
these comments.
Inventory as of this Action
Requested
Previously Approved
36 Months From Approved
0
0
0
0
0
0
0
0
0
The proposed rule is intended to
update the standards for FDA acceptance of data from clinical
studies conducted outside the United States and to help ensure the
protection of human subjects and the quality and integrity of data
obtained from these studies. As part of this proposed rule, we are
also proposing to amend the IDE and 510(k) regulations to address
the requirements for FDA acceptance of data from clinical studies
conducted inside the United States. The proposed amendments are
intended to provide consistency in FDA requirements for acceptance
of clinical data, whatever the application or submission type. For
data from clinical studies conducted inside the United States, we
propose to require statements in 510(k) submissions and IDE
applications that are similar to those currently required for PMA
applications, to help ensure the protection of human subjects and
the quality and integrity of data obtained from these studies. The
proposed rule would require additional maintenance, retention, and
submission of documents indicating (1) clinical studies conducted
outside the United States and used to support IDE or device
marketing applications or submissions are conducted in accordance
with GCP, and (2) availability of data for FDA inspection, if
deemed necessary. The information in this section (and in section
#1) allows reviewers to assess the appropriateness and adequacy of
the clinical trial design, data collection plans, and protect human
subjects participating in medical device trials.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.